← boardnext 2027-04-01
PBLS
Parabilis Medicines, Inc.distress 3/10 · well-funded / low risk$31.32+2%today-1% from 52w high
Lead: Cancer
Revenue
pre-revenue
Liquidity
$329M
Runway
2.7 yrs
Shares 1y
—
Price & events
-0.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.7%
1D
+7.8%
1W
+13.8%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
-0.9%
All
Overview
- Volume
- 34.88K
- 52 Week Range
- $25.01 – $31.60
- Float Shares
- 2.49M
- Short %
- 2.29%
- % Held by Insiders
- 3.78%
- % Held by Institutions
- 54.11%
- RVOL
- 0.04x
Pipeline stages · 1 programs
FOG-001, mFOLFOX-6, Nivolumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-04-01 Estimated 50% readout ~2027-05-16 | Phase 1/2 | FOG-001, mFOLFOX-6, Nivolumab | Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, FAP, Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $42 (+33% upside) · 4 analysts
- 2026-07-06GuggenheimBuy
- 2026-07-06Leerink PartnersOutperform
- 2026-07-06B of A SecuritiesBuy
Competitors — Cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- AMGNAMGEN INC$195.4B · D3
- PFEPFIZER INC$142.2B · D3
- BNTXBioNTech SE$23.1B · D1
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com Canada
- 2026-07-22RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan
- 2026-07-14Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat
- 2026-07-13PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co
- 2026-07-13Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS) - MarketBeat
- 2026-07-06Guggenheim initiates Parabilis Medicines stock with buy rating By Investing.com - Investing.com UK
- 2026-07-06Leerink initiates Parabilis Medicines stock with Outperform rating - Investing.com
- 2026-07-06BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.